Xihu Lingxi closes angel+ round to commercialise its Mandarin brain-computer interface
What's the deal? Xihu Lingxi, a Chinese startup developing neural prosthetic systems for speech and motor rehabilitation, has closed an angel+ funding round worth tens of millions of yuan. The round was co-led by MSA Capital, Kinzon CapitalDealroom has a profile for this one. Try Dealroom →, Qizhen Fund, and Nanjing Innovation Investment GroupDealroom has a profile for this one. Try Dealroom →.
The company builds low-power, high-throughput brain-computer interface (BCI) chips and neural decoding algorithms designed to restore communication and movement for patients with speech and motor disorders.
Why now? The funds will go toward commercialising Xihu Lingxi's BCI chip technology and its Mandarin Chinese language decoding system — a technically distinct challenge from the English-language decoding work that dominates the global BCI field. The startup aims to accelerate the transition from lab-stage research to real clinical applications.
What could go wrong? BCI technology remains in its early stages worldwide, with significant regulatory, technical, and adoption hurdles. Decoding natural speech from brain signals is one of the hardest problems in neuroscience, and commercialisation timelines in medical devices are notoriously long.
The signal: Xihu Lingxi's raise reflects growing investor appetite for BCI startups in China, particularly those tackling language-specific neural decoding. As global competitors like Neuralink and Synchron push forward, China is building its own BCI ecosystem — with companies focused on the unique computational challenges of Mandarin. The startup sits at the intersection of two hot themes: intelligent medical devices and brain-computer interfaces as a platform technology.
